Cost-effectiveness of the adjuvanted respiratory syncytial virus prefusion F protein (RSVPreF3) vaccine in Japanese adults aged 50–59 years at increased risk of severe RSV disease and those aged ≥60 years

Background Respiratory syncytial virus (RSV) can cause substantial morbidity and mortality in adults aged 50–59 years at increased risk of severe RSV disease due to specific underlying conditions (i.e. ’50–59 years at-increased-risk [AIR] population’), and in older adults aged ≥60 years (i.e. ‘≥60 y...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Kentaro Tajima, Eleftherios Zarkadoulas, Joost Simons, Daisuke Kurai, Mei Grace, Jonathan Graham, Yufan Ho, Frederik Verelst
Format:	Artigo
Sprog:	Inglês
Udgivet:	Taylor & Francis Group 2026-12-01
Serier:	Expert Review of Vaccines
Fag:	Adjuvanted RSV prefusion F protein vaccine at-increased-risk comorbidities cost-effectiveness Japan older adults
Online adgang:	https://www.tandfonline.com/doi/10.1080/14760584.2026.2626921
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!